Melanoma Dispatch
2.6K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

Palliative Chemotherapy: Harms and Benefits Weighed in New Study

"Palliative chemotherapy is treatment designed for terminal cancer patients to prolong survival and ease symptoms but not cure disease. Now, researchers have found that the therapy comes with certain harms, which they say need to be addressed...


"Overall, the team found that terminal cancer patients who receive chemotherapy during the last months of their lives are less likely to die where they wish and are more likely to undergo invasive medical procedures - including CPR and mechanical ventilation - than patients who did not receive the therapy."

Cancer Commons's insight:

Medical News Today  |  Mar 5, 2014

more...
Cancer Commons's curator insight, March 5, 2014 2:21 PM

Medical News Today  |  Mar 5, 2014

Cancer Commons's curator insight, March 5, 2014 2:21 PM

Medical News Today  |  Mar 5, 2014

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

New Treatment Proposed to Prevent Devastating Intestinal Inflammation in Cancer Patients

New Treatment Proposed to Prevent Devastating Intestinal Inflammation in Cancer Patients | Melanoma Dispatch | Scoop.it

"Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation – has been achieved by an international team of researchers. Mucositis is a strong inflammatory reaction of the mucosal lining of the digestive system, particularly the gut. Mucositis is often a major reason for premature suspension of anti-cancer therapy. As of today, there has been no effective means of preventing mucositis or its treatment."

Cancer Commons's insight:

ScienceDaily  |  Feb 18, 2014 

more...
Cancer Commons's curator insight, February 28, 2014 4:49 PM

ScienceDaily  |  Feb 18, 2014 

Cancer Commons's curator insight, February 28, 2014 4:51 PM

ScienceDaily  |  Feb 18, 2014 

Rescooped by Cancer Commons from Lung Cancer Dispatch
Scoop.it!

Enhancement of Chemotherapy by Prevention of Tumor Cell Repair

"The body naturally tries to repair lesions in the DNA of tumor cells, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team of scientists has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy."

Cancer Commons's insight:

ScienceDaily  |  Feb 20, 2014

more...
Cancer Commons's curator insight, February 28, 2014 4:51 PM

ScienceDaily  |  Feb 20, 2014

Cancer Commons's curator insight, February 28, 2014 4:52 PM

ScienceDaily  |  Feb 20, 2014

Scooped by Cancer Commons
Scoop.it!

Extended Follow-up in BRIM-3 Shows Prolonged Survival With Vemurafenib in BRAF V600E/K Mutation–Positive Melanoma

Extended Follow-up in BRIM-3 Shows Prolonged Survival With Vemurafenib in BRAF V600E/K Mutation–Positive Melanoma | Melanoma Dispatch | Scoop.it

"In the BRIM-3 trial, vemurafenib (Zelboraf) was associated with improved progression-free and overall survival vs dacarbazine in patients with advanced BRAF V600 mutation–positive melanoma. In an extended follow-up reported in The Lancet Oncology, McArthur et al found that superior survival outcomes were maintained and were present in both theBRAF V600E and BRAF V600K mutation subgroups."


Editor's note: Read more about vemurafenib here: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a612009.html

Cancer Commons's insight:

The ASCO Post  |  Feb 12, 2014

more...
No comment yet.